Abstract
Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Keywords: drug design, molecular imaging, neurodegeneration, nicotine, orthosteric ligand, acetyl-choline, tomography, positron, radioligands, radiotracers
Current Drug Targets
Title:Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Volume: 13 Issue: 5
Author(s): Peter Brust, Dan Peters, Winnie Deuther-Conrad
Affiliation:
Keywords: drug design, molecular imaging, neurodegeneration, nicotine, orthosteric ligand, acetyl-choline, tomography, positron, radioligands, radiotracers
Abstract: Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.
Export Options
About this article
Cite this article as:
Peter Brust, Dan Peters, Winnie Deuther-Conrad , Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398955
DOI https://dx.doi.org/10.2174/138945012800398955 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry 5q- syndrome
Current Pharmaceutical Design Challenges and Opportunities for Bacterial Vaccine Development in the 21<sup>st</sup> Century
Current Pharmaceutical Biotechnology A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Molecular Mechanisms of Cardiac Voltage-Gated Potassium Channelopathies
Current Pharmaceutical Design Differential Network Analysis in Human Cancer Research
Current Pharmaceutical Design The Comparison of Different Planes in Breast Ultrasonography
Current Medical Imaging Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nanotechnology as an Adjunct Tool for Transplanting Engineered Cells and Tissues
Current Molecular Medicine An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review
Current Drug Delivery Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design